ARKG is trading at $49.80, up +5.44%, as constructive cardiovascular data presented at the ESC Congress 2026 benefits biotech and genomics sentiment.
- New RNAi therapeutic results from Alnylam and cardiometabolic data from Ionis contributed to the constructive backdrop.
- The rally comes as broader U.S. markets are lower, pointing to a sector-specific move; additional ESC trial coverage reinforced healthcare innovation optimism, though no single ARKG holding explains the entire gain.